Arrowhead Research | ARWR - Assets



Arrowhead Research reported $1.38B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Arrowhead Research USD 1.38B 192.89M Jun/2025
Incyte USD 5.82B 71.99M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
Ligand Pharmaceuticals USD 948.6M 43.17M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Moderna USD 12.01B 694M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
TG Therapeutics USD 702.61M 45.92M Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025
Xencor USD 879.42M 25.26M Jun/2025